本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Sarepta Therapeutics

23.77
+6.1634.98%
盤後23.64-0.1300-0.55%16:11 EDT
成交量:1,698.24萬
成交額:3.78億
市值:24.91億
市盈率:-3.33
高:23.85
開:19.76
低:19.67
收:17.61
52周最高:76.26
52周最低:10.42
股本:1.05億
流通股本:9,516.78萬
量比:6.75
換手率:17.84%
股息:- -
股息率:- -
每股收益(TTM):-7.1300
每股收益(LYR):-7.1300
淨資產收益率:-53.47%
總資產收益率:-11.24%
市淨率:2.18
市盈率(LYR):-3.33

資料載入中...

公司資料

公司名字:
Sarepta Therapeutics
交易所:
NASDAQ
成立時間:
1980
員工人數:
835
公司地址:
215 First Street,Suite 415,Cambridge,Massachusetts,United States
郵編:
02142
電話:
傳真:
- -
簡介:
Sarepta Therapeutics, Inc.於1980年7月22日在俄勒岡州註冊成立。該公司是一家商業化階段的生物製藥公司,專註於發現和開發獨特的RNA靶向療法、基因療法和其他遺傳治療方式,用於治療罕見病。它已開發出多種獲批的杜氏肌營養不良症治療藥物,並正在推進針對其他神經肌肉和骨骼疾病的候選藥物。

董事

名稱
職位
Douglas Ingram
Director,Chief Executive Officer
Claude Nicaise
Independent Director
Deirdre P. Connelly
Independent Director
Hans Wigzell
Independent Director
Kathryn Jean Boor
Independent Director
M. Kathleen Behrens
Chairwoman of the Board
Michael A. Chambers
Independent Director
Richard J. Barry
Independent Director
Stephen L. Mayo
Independent Director

股東

名稱
職位
Douglas Ingram
Director,Chief Executive Officer
Ian Estepan
President and Chief Operating Officer
Ryan Wong
Executive Vice President, Chief Financial Officer,Principal Accounting Officer
Cristin Rothfuss
Executive Vice President, Chief General Counsel and Corporate Secretary
Louise Rodino Klapac
President, Research and Development and Technical Operations